8-KFiled May 14, 8:00 PM ET

BioXcel Therapeutics Reports Q1 2026 Financial Results

$BTAI · BioXcel Therapeutics, Inc.

Research Summary

AI-generated summary of this SEC filing

Updated

BioXcel Therapeutics Reports Q1 2026 Financial Results

What Happened
BioXcel Therapeutics, Inc. announced its financial results for the three months ended March 31, 2026 and provided a business update via a press release issued on May 15, 2026. The company furnished that press release as Exhibit 99.1 to its Current Report on Form 8-K (filed May 15, 2026), which is incorporated by reference into the filing.

Key Details

  • Filing date: May 15, 2026; the press release covers quarterly results for the period ended March 31, 2026.
  • The press release is furnished as Exhibit 99.1 to the Form 8-K.
  • The Form 8-K includes Inline XBRL cover page tags (interactive data) per the exhibits disclosure.

Why It Matters
This 8-K notifies investors that BioXcel has released its latest quarterly earnings and a business update—information investors use to assess recent performance, revenue/earnings trends, cash position, and near-term priorities. Investors should read the Exhibit 99.1 press release for the specific financial figures and operational details reported for Q1 2026.